Spots Global Cancer Trial Database for Phase 2 Study of Dacomitinib in NSCLC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 2 Study of Dacomitinib in NSCLC
Official Title: A Single-arm, Open-label, Phase 2 Study of Dacomitinib With or Without Dose Titration for the First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Subjects With an Epidermal Growth Factor Receptor (EGFR) Activation Mutation
Study ID: NCT04027647
Interventions
Study Description
Brief Summary: This is a multi-national, multi-centre, single-arm, open-label, Phase 2 clinical study of the efficacy and safety of first-line treatment with dacomitinib, with or without dose titration, in subjects with newly diagnosed stage IIIB/IIIC/IV or recurrent EGFR-mutation-positive non-small cell lung cancer (NSCLC). National Cancer Centre Singapore is the lead sponsor acting in a coordinating capacity and the rest of the participating sites are sponsors of their own individual sites.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Prince of Wales Hospital, Hong Kong, , Hong Kong
Dong-A University Hospital, Busan, , Korea, Republic of
Seoul National University Hospital, Seoul, , Korea, Republic of
Sarawak General Hospital, Kuching, Sarawak, Malaysia
University Malaya Medical Centre, Kuala Lumpur, , Malaysia
Beacon Hospital, Petaling Jaya, , Malaysia
National Cancer Centre Singapore, Singapore, , Singapore
Phramongkutklao Hospital, Bangkok, , Thailand
Ramathibodi Hospital, Bangkok, , Thailand
Contact Details
Name: Daniel Tan, BSc, MBBS, PhD
Affiliation: National Cancer Centre Singapore (Lead Sponsor)
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
